Results 1 to 1 of 1
04-08-2009, 05:10 PM #1
FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market
Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. By June 8, 2009, Raptiva will no longer be available in the United States.
The Following User Says Thank You to budget For This Useful Post: